Trial Profile
A randomised controlled phase I study to determine the safety and immunogenicity of a novel prostate cancer vaccine with and without low dose cyclophosphamide in low and intermediate risk localised prostate cancer
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Jan 2024
Price :
$35
*
At a glance
- Drugs ChAdOx1-MVA 5T4 vaccine (Primary) ; Cyclophosphamide
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Jun 2018 According to a Vaccitech media release, this study is funded by the European Commission FP7 programme.
- 04 Jun 2018 Results presented in a Vaccitech Media Release.
- 04 Jun 2018 According to a Vaccitech media release, data were presented at the 2018 American Society of Clinical Oncology (ASCO) annual meeting.